Radicava

Option Care Enterprises will become a national provider of home infusion services for Radicava (edaravone), the first treatment for amyotrophic lateral sclerosis that the United States has approved in more than 20 years. Bannockburn, Illinois-based Option Care will provide the services under an agreement with Mitsubishi Tanabe Pharma America,…

This segment from CBS Boston is sharing the good news that the FDA-approved drug Radicava for the treatment of amyotrophic lateral sclerosis (ALS) is now available for patients in the U.S. MORE: Nine things to know about Radicava The breakthrough drug has been found to slow down the…

William White, who entered Ohio State University on a football scholarship, played for the Buckeyes and earned an engineering degree before going on to an 11-year NFL career with the Detroit Lions, the Kansas City Chiefs, and the Atlanta Falcons. William White Now retired from the NFL and…

Radicava (edaravone), the first new medication for amyotrophic lateral sclerosis (ALS) in 22 years, is now available in the United States. Approved May 5 by the U.S. Food and Drug Administration (FDA) for all U.S. adults diagnosed with ALS, Radicava has been shown to slow the loss of physical function in ALS patients by…

MT Pharma America, maker of Radicava (edaravone), an intravenous treatment for adults with amyotrophic lateral sclerosis (ALS), has changed its name to Mitsubishi Tanabe Pharma America (MTPA). In February 2016, MTPA’s parent company, the Japanese Mitsubishi Tanabe Pharma Corporation (MTPC), launched MT Pharma America to develop and…

On May 5, the FDA approved the first new treatment in 22 years for amyotrophic lateral sclerosis (ALS). The drug, Radicava (edaravone), has been found to slow down the decline of physical ability in ALS patients by a third. Find out more about the FDA approval of Radicava here.  MORE:…